Protocol for the Examination of Specimens From Patients With Cancers of the Pharynx

Version: Pharynx 4.0.0.0  Protocol Posting Date: June 2017
Includes pTNM requirements from the 8th Edition, AJCC Staging Manual

For accreditation purposes, this protocol should be used for the following procedures AND tumor types:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resection</td>
<td>Includes specimens designated pharynx (oropharynx, nasopharynx, hypopharynx) including the base of the tongue, tonsils, soft palate, and uvula</td>
</tr>
</tbody>
</table>

**Tumor Type** | **Description**                                                                                                                                 |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinoma</td>
<td>Includes squamous cell carcinoma, neuroendocrine carcinoma, and minor salivary gland carcinoma</td>
</tr>
<tr>
<td>Mucosal Melanoma</td>
<td></td>
</tr>
</tbody>
</table>

This protocol is NOT required for accreditation purposes for the following:

<table>
<thead>
<tr>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsy</td>
</tr>
<tr>
<td>Primary resection specimen with no residual cancer (eg, following neoadjuvant therapy)</td>
</tr>
<tr>
<td>Cytologic specimens</td>
</tr>
</tbody>
</table>

The following tumor types should NOT be reported using this protocol:

<table>
<thead>
<tr>
<th>Tumor Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarcoma (consider the Soft Tissue protocol)</td>
</tr>
<tr>
<td>Lymphoma (consider the Hodgkin or non-Hodgkin Lymphoma protocols)</td>
</tr>
</tbody>
</table>

Authors

Raja R. Seethala, MD*; Martin J. Bullock, MD; Diane L. Carlson, MD; Robert L. Ferris, MD, PhD; Louis B. Harrison, MD; Jonathan B. McHugh, MD; Jason Pettus, MD; Mary S. Richardson, MD; Jatin Shah, MD; Lester D.R. Thompson, MD; Ilan Weinreb, MD; Bruce M. Wenig, MD

With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.

* Denotes primary author. All other contributing authors are listed alphabetically.
Accreditation Requirements
This protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes, only the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format.

- **Core data elements** are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is "not applicable" or "cannot be determined."
- **Conditional data elements** are only required to be reported if applicable as delineated in the protocol. For instance, the total number of lymph nodes examined must be reported, but only if nodes are present in the specimen.
- **Optional data elements** are identified with "+" and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards.

The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (ie, secondary consultation, second opinion, or review of outside case at second institution).

Synoptic Reporting
All core and conditionally required data elements outlined on the surgical case summary from this cancer protocol must be displayed in synoptic report format. Synoptic format is defined as:

- Data element: followed by its answer (response), outline format without the paired "Data element: Response" format is NOT considered synoptic.
- The data element must be represented in the report as it is listed in the case summary. The response for any data element may be modified from those listed in the case summary, including "Cannot be determined" if appropriate.
- Each diagnostic parameter pair (Data element: Response) is listed on a separate line or in a tabular format to achieve visual separation. The following exceptions are allowed to be listed on one line:
  - Anatomic site or specimen, laterality, and procedure
  - Pathologic Stage Classification (pTNM) elements
  - Negative margins, as long as all negative margins are specifically enumerated where applicable
- The synoptic portion of the report can appear in the diagnosis section of the pathology report, at the end of the report or in a separate section, but all Data element: Responses must be listed together in one location. Organizations and pathologists may choose to list the required elements in any order, use additional methods in order to enhance or achieve visual separation, or add optional items within the synoptic report. The report may have required elements in a summary format elsewhere in the report IN ADDITION TO but not as replacement for the synoptic report i.e. all required elements must be in the synoptic portion of the report in the format defined above.

**CAP Laboratory Accreditation Program Protocol Required Use Date: March 2018**
*Beginning January 1, 2018, the 8th edition AJCC Staging Manual should be used for reporting pTNM.*

**CAP Pharynx Protocol Summary of Changes**

The following data elements were modified:
Pathologic Stage Classification (pTNM, AJCC 8th Edition)
Histologic Type
Extranodal Extension (ENE)

The following data element was deleted:
Ancillary Studies
Surgical Pathology Cancer Case Summary

Protocol posting date: June 2017

PHARYNX (OROPHARYNX, HYPOPHARYNX, NASOPHARYNX):

Select a single response unless otherwise indicated.

Procedure (select all that apply)
___ Excision
___ Tonsillectomy
___ Laryngopharyngectomy
___ Neck (lymph node) dissection (specify): ____________________________
___ Other (specify): ____________________________
___ Not specified

Tumor Site (Note A)\(^\#\)
___ Oropharynx
   + ___ Palatine tonsil
   + ___ Base of tongue, including lingual tonsil
   + ___ Soft palate
   + ___ Uvula
   + ___ Pharyngeal wall (posterior)
___ Nasopharynx
   + ___ Nasopharyngeal tonsils (adenoids)
___ Hypopharynx
   + ___ Piriform sinus
   + ___ Postcricoid
   + ___ Pharyngeal wall (posterior and/or lateral)
___ Other (specify): ____________________________
___ Not specified

\(^\#\) Note: Multiple subsites may be selected.

Tumor Laterality (select all that apply)
___ Left
___ Right
___ Midline
___ Not specified

Tumor Focality
___ Unifocal
___ Multifocal
___ Cannot be determined

Tumor Size
Greatest dimension (centimeters): ___ cm
+ Additional dimensions (centimeters): ___ x ___ cm
___ Cannot be determined (explain): ____________________________

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
Histologic Type (Notes B and C)

Carcinomas of the Oropharynx and Hypopharynx
___ Human papillomavirus (HPV)-mediated (positive) squamous cell carcinoma (oropharynx only)
___ HPV-unrelated (negative) squamous cell carcinoma (oropharynx)
___ Oropharyngeal squamous cell carcinoma, HPV status unknown
___ Hypopharyngeal squamous cell carcinoma

Squamous Cell Carcinoma and Variants (select all that apply)
___ Squamous cell carcinoma, conventional (keratinizing)
___ Squamous cell carcinoma, nonkeratinizing
___ Acantholytic squamous cell carcinoma
___ Adenosquamous carcinoma
___ Basaloid squamous cell carcinoma
___ Papillary squamous cell carcinoma
___ Spindle cell squamous cell carcinoma
___ Verrucous squamous cell carcinoma
___ Lymphoepithelial carcinoma (non-nasopharyngeal)

Carcinomas of the Nasopharynx
___ Keratinizing squamous cell carcinoma
___ Nonkeratinizing squamous cell carcinoma
___ Basaloid squamous cell carcinoma

Carcinomas of Minor Salivary Glands
___ Mucoepidermoid carcinoma, low grade
___ Mucoepidermoid carcinoma, intermediate grade
___ Mucoepidermoid carcinoma, high grade
___ Adenoid cystic carcinoma, tubular pattern#  
   + Specify percentage of solid component: ____%
___ Adenoid cystic carcinoma, cribriform pattern#  
   + Specify percentage of solid component: ____%
___ Adenoid cystic carcinoma, solid pattern#  
   + Specify percentage of solid component: ____%
___ Acinic cell carcinoma
___ Polymorphous adenocarcinoma, classic, low grade
___ Polymorphous adenocarcinoma, classic, intermediate grade
___ Polymorphous adenocarcinoma, classic, high grade
___ Polymorphous adenocarcinoma, cribriform (cribriform adenocarcinoma of salivary origin), low grade
___ Polymorphous adenocarcinoma, cribriform (cribriform adenocarcinoma of salivary origin), intermediate grade
___ Polymorphous adenocarcinoma, cribriform (cribriform adenocarcinoma of salivary origin), high grade
___ (Mammary analogue) Secretory carcinoma
___ Salivary duct carcinoma
___ Epithelial-myoepithelial carcinoma
___ (Hyalinizing) clear cell carcinoma
___ Adenocarcinoma, not otherwise specified, low grade
___ Adenocarcinoma, not otherwise specified, intermediate grade
___ Adenocarcinoma, not otherwise specified, high grade
___ Basal cell adenocarcinoma
___ Carcinosarcoma (true malignant mixed tumor)
___ Intraductal carcinoma, low grade
___ Intraductal carcinoma, high grade
___ Lymphoepithelial carcinoma
___ Myoepithelial carcinoma
___ Oncocytic carcinoma

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
Preexisting pleomorphic adenoma component (required in addition to salivary carcinoma type, if applicable)
___ Carcinoma ex pleomorphic adenoma, minimally invasive
___ Carcinoma ex pleomorphic adenoma, invasive
___ Carcinoma ex pleomorphic adenoma, intracapsular (noninvasive)

# Note: If multiple patterns present, select predominant pattern unless solid pattern is greater than 30%, in which case should select solid pattern

Adenocarcinomas (Non-Salivary Gland Type)
___ Nasopharyngeal papillary adenocarcinoma

Neuroendocrine Carcinoma
___ Small cell neuroendocrine carcinoma, HPV negative
___ Small cell neuroendocrine carcinoma, HPV positive
___ Large cell neuroendocrine carcinoma, HPV negative
___ Large cell neuroendocrine carcinoma, HPV positive
___ Mucosal melanoma
___ Carcinoma, type cannot be determined
___ Other histologic type not listed (specify):

Histologic Grade (Note C) (required for squamous cell carcinomas [HPV-unrelated/negative) only])
___ G1: Well differentiated
___ G2: Moderately differentiated
___ G3: Poorly differentiated
___ Other (specify): ____________________________
___ GX: Cannot be assessed

+ Tumor Extension
+ Specify: ____________________________

Margins (select all that apply) (Notes D and E)
___ Cannot be assessed
___ Uninvolved by invasive tumor
   Distance from closest margin (millimeters): ____ mm
   Specify location of closest margin, per orientation, if possible: ____________________________
   + Location and distance of other close margins: ____________________________
___ Involved by invasive tumor
___ Uninvolved by high-grade dysplasia/in situ disease #
   Distance from closest margin (millimeters): ____ mm
   Specify location of closest margin, per orientation, if possible: ____________________________
___ Involved by high-grade dysplasia/in situ disease #
   Specify margin(s), per orientation, if possible: ____________________________

# Note: Applicable only to nonoropharyngeal and HPV-negative oropharyngeal squamous cell carcinoma and histologic variants, and required only if margins uninvolved by invasive carcinoma.

Lymphovascular Invasion
___ Not identified
___ Present
___ Cannot be determined

# Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
Perineural Invasion (Note F)
___ Not identified
___ Present
___ Cannot be determined

Regional Lymph Nodes (Note G)
___ No lymph nodes submitted or found

Lymph Node Examination (required only if lymph nodes present in specimen)

Number of Lymph Nodes Involved: ________
___ Number cannot be determined (explain): ____________________________

Number of Lymph Nodes Examined: _______
___ Number cannot be determined (explain): ____________________________

Lymph Node Metastasis Specific Characteristics (required for all histologies except mucosal melanoma, and only if lymph nodes involved)

Laterality of Lymph Nodes Involved
___ Ipsilateral (including midline)
___ Contralateral
___ Bilateral
___ Cannot be determined

Size of Largest Metastatic Deposit (centimeters): ____ cm

Extranodal Extension (ENE) (required only for HPV-unrelated/negative oropharyngeal and hypopharyngeal carcinomas)
___ Not identified
___ Present
  + Distance from lymph node capsule (millimeters): _____ mm
  + ENEma (>2 mm)
  + ENEmi (≤2 mm)
___ Cannot be determined

Pathologic Stage Classification (pTNM, AJCC 8th Edition) (Note H)

Note: Reporting of pT, pN, and (when applicable) pM categories is based on information available to the pathologist at the time the report is issued. Only the applicable T, N, or M category is required for reporting; their definitions need not be included in the report. The categories (with modifiers when applicable) can be listed on 1 line or more than 1 line.

TNM Descriptors (required only if applicable) (select all that apply)
___ m (multiple primary tumors)
___ r (recurrent)
___ y (posttreatment)

For All Carcinomas

Primary Tumor (pT)

For HPV-Mediated (Positive) Oropharynx
___ pT0: No primary identified
___ pT1: Tumor 2 cm or smaller in greatest dimension
___ pT2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension
___ pT3: Tumor more than 4 cm in greatest dimension or extension to lingual surface of epiglottis

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
For **HPV-Unrelated (Negative) Oropharynx**

- **pTX**: Primary tumor cannot be assessed
- **pTis**: Carcinoma in situ
- **pT1**: Tumor 2 cm or smaller in greatest dimension
- **pT2**: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension
- **pT3**: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis
- **pT4**: Moderately advanced or very advanced local disease
  - **pT4a**: Moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible
  - **pT4b**: Very advanced local disease. Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery

*Note: Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of larynx.*

---

For **Nasopharynx**

- **pTX**: Primary tumor cannot be assessed
- **pT0**: No tumor identified, but EBV-positive cervical node(s) involvement
- **pT1**: Tumor confined to nasopharynx, or extension to oropharynx and/or nasal cavity without parapharyngeal involvement
- **pT2**: Tumor with extension to parapharyngeal space, and/or adjacent soft tissue involvement (medial pterygoid, lateral pterygoid, prevertebral muscles)
- **pT3**: Tumor with infiltration of bony structures at skull base, cervical vertebra, pterygoid structures, and/or paranasal sinuses
- **pT4**: Tumor with intracranial extension, involvement of cranial nerves, hypopharynx, orbit, parotid gland, and/or extensive soft tissue infiltration beyond the lateral surface of the lateral pterygoid muscle

---

For **Hypopharynx**

- **pTX**: Primary tumor cannot be assessed
- **pTis**: Carcinoma in situ
- **pT1**: Tumor limited to one subsite of hypopharynx and/or 2 cm or smaller in greatest dimension
- **pT2**: Tumor invades more than one subsite of hypopharynx or an adjacent site, or measures larger than 2 cm but not larger than 4 cm in greatest dimension without fixation of hemilarynx
- **pT3**: Tumor measures larger than 4 cm in greatest dimension or with fixation of hemilarynx or extension to esophagus
- **pT4**: Moderately advanced and very advanced local disease
  - **pT4a**: Moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible
  - **pT4b**: Very advanced local disease. Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery

*Note: Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of larynx.*

---

**Regional Lymph Nodes (pN) (Note G)**

For **HPV-Mediated (Positive) Oropharynx**

- **pNX**: Regional lymph nodes cannot be assessed
- **pN0**: No regional lymph node metastasis
- **pN1**: Metastasis in 4 or fewer lymph nodes
- **pN2**: Metastasis in more than 4 lymph nodes

* Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
For HPV-Unrelated (Negative) Oropharynx and Hypopharynx

- **pNX**: Regional lymph nodes cannot be assessed
- **pN0**: No regional lymph node metastasis
- **pN1**: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(−)
- **pN2**: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+) or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)
- **pN2a**: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+); or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)
- **pN2b**: Metastasis in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−)
- **pN2c**: Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)
- **pN3**: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−); or in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+) or multiple ipsilateral, contralateral or bilateral nodes, any with ENE(+) or a single contralateral node 3 cm or smaller and ENE(+) or a single contralateral node 3 cm or smaller and ENE(+)
- **pN3a**: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−)
- **pN3b**: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+) or multiple ipsilateral, contralateral or bilateral nodes any with ENE(+) or a single contralateral node 3 cm or smaller and ENE(+) or a single contralateral node 3 cm or smaller and ENE(+)

*Midline nodes are considered ipsilateral nodes.*

**Note:** Pathological ENE should be recorded as ENE(−) or ENE(+).

**Note:** Measurement of the metastatic focus in the lymph nodes is based on the largest metastatic deposit size, which may include matted or fused lymph nodes.

For Nasopharynx

- **pNX**: Regional lymph nodes cannot be assessed
- **pN0**: No regional lymph node metastasis
- **pN1**: Unilateral metastasis in cervical lymph node(s) and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage
- **pN2**: Bilateral metastasis in cervical lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage
- **pN3**: Unilateral or bilateral metastasis in cervical lymph node(s), larger than 6 cm in greatest dimension, and/or extension below the caudal border of cricoid cartilage

Distant Metastasis (**pM**) (required only if confirmed pathologically in this case)

- **pM1**: Distant metastasis
  Specify site(s), if known: ____________________________

For Mucosal Melanoma

**Primary Tumor (**p**T)**

- **pT3**: Tumors limited to the mucosa and immediately underlying soft tissue, regardless of thickness or greatest dimension; for example, polypoid nasal disease, pigmented or nonpigmented lesions of the oral cavity, pharynx, or larynx
- **pT4**: Moderately advanced or very advanced disease
  - **pT4a**: Moderately advanced disease. Tumor involving deep soft tissue, cartilage, bone, or overlying skin.
  - **pT4b**: Very advanced disease. Tumor involving brain, dura, skull base, lower cranial nerves (IX, X, XI, XII), masticator space, carotid artery, prevertebral space, or mediastinal structures.

* Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
Regional Lymph Nodes (pN)
___ pNX: Regional lymph nodes cannot be assessed
___ pN0: No regional lymph node metastases
___ pN1: Regional lymph node metastases present

Distant Metastasis (pM) (required only if confirmed pathologically in this case)
___ pM1: Distant metastasis present

Specify site(s), if known: ____________________________

+ Additional Pathologic Findings (select all that apply) (Note I)
+ ___ None identified
+ ___ Keratinizing dysplasia, mild#
+ ___ Keratinizing dysplasia, moderate#
+ ___ Keratinizing dysplasia, severe (carcinoma in situ)#
+ ___ Nonkeratinizing dysplasia, mild#
+ ___ Nonkeratinizing dysplasia, moderate#
+ ___ Nonkeratinizing dysplasia, severe (carcinoma in situ)#
+ ___ Inflammation (specify type): ____________________________
+ ___ Squamous metaplasia
+ ___ Epithelial hyperplasia
+ ___ Colonization, fungal
+ ___ Colonization, bacterial
+ ___ Other (specify): ____________________________

# Note: Applicable only to nonoropharyngeal and HPV-negative oropharyngeal squamous cell carcinoma and histologic variants, and required only if margins uninvolved by invasive carcinoma.

Ancillary Studies (if applicable)

Note: For reporting molecular testing and other cancer biomarker testing results, the CAP Head and Neck Biomarker Template should be used. Pending biomarker studies should be listed in the Comments section of this report. Note that some form of high risk HPV testing is required for staging of oropharyngeal squamous cell carcinoma, and p16 immunohistochemistry is acceptable as a surrogate marker of HPV status in oropharynx.

+ Comment(s)
Explanatory Notes

Scope of Guidelines
The reporting of pharynx cancer including the lip is facilitated by the provision of a case summary illustrating the features required for comprehensive patient care. However, there are many cases in which the individual practicalities of applying such a case summary may not be straightforward. Common examples include finding the prescribed number of lymph nodes, trying to determine the levels of the radical neck dissection, and determining if isolated tumor cells in a lymph node represent metastatic disease. Case summaries have evolved to include clinical, radiographic, morphologic, immunohistochemical, and molecular results in an effort to guide clinical management. Adjuvant and neoadjuvant therapy can significantly alter histologic findings, making accurate classification an increasingly complex and demanding task. This protocol tries to remain simple while still incorporating important pathologic features as proposed by the American Joint Committee on Cancer (AJCC) cancer staging manual, the World Health Organization (WHO) classification of tumors, the TNM classification,¹ the American College of Surgeons Commission on Cancer, and the International Union on Cancer (UICC). This protocol is to be used as a guide and resource, an adjunct to diagnosing and managing cancers of the pharynx in a standardized manner. It should not be used as a substitute for dissection or grossing techniques and does not give histologic parameters to reach the diagnosis. Subjectivity is always a factor, and elements listed are not meant to be arbitrary but are meant to provide uniformity of reporting across all the disciplines that use the information. It is a foundation of practical information that will help to meet the requirements of daily practice to benefit both clinicians and patients alike.

A. Anatomical Sites and Subsites for Pharynx
The pharynx is divided into 3 parts including the nasopharynx, oropharynx, and hypopharynx (Figure 1).

Oropharynx (Figure 1)
The oropharynx is the portion of the continuity of the pharynx extending from the plane of the superior surface of the soft palate to the superior surface of the hyoid bone or floor of the vallecula.²,³ The contents of the oropharynx include:
- soft palate
- palatine tonsils
- anterior and posterior tonsillar pillars
- tonsillar fossa and tonsillar (faucial) pillars
- uvula
- base of tongue, including the lingual tonsils
- vallecula
- posterior oropharyngeal wall

Nasopharynx (Figure 1)
The nasopharynx is situated behind the nasal cavity and above the soft palate; it begins anteriorly at the posterior choana and extends along the plane of the airway to the level of the free border of the soft palate.⁴ The contents of the nasopharynx include:
- nasopharyngeal tonsils (adenoids) lie along the posterior and lateral of the nasopharynx
- orifice of Eustachian tube lies along the lateral aspects of the nasopharyngeal wall
- fossa of Rosenmüller

Hypopharynx (Figure 1)
The hypopharynx is the portion of the pharynx extending from the plane of the superior border of the hyoid bone (or floor of the vallecula) to the plane corresponding to the lower border of the cricoid cartilage.² The contents of the hypopharynx include:
- piriform sinus (right and left) - represents part of the hypopharynx which expands bilaterally and forward around the sides of the larynx and lies between the larynx and the thyroid cartilage
- lateral and posterior hypopharyngeal walls
- postcricoid region extending from the level of the arytenoid cartilage and connecting folds to the inferior border of the cricoid cartilage; it connects the 2 piriform sinuses, thereby forming the anterior wall of the hypopharynx

Waldeyer ring is formed by a ring or group of extranodal lymphoid tissues about the upper end of the pharynx (Figure 2) which consists of the:
- palatine tonsils
- pharyngeal tonsils (adenoids)
- base of tongue/lingual tonsils
- adjacent submucosal lymphatics
B. Histologic Type
A modification of the WHO classification of carcinomas of the oropharynx, the nasopharynx, and the hypopharynx is shown below. This list may not be complete. This protocol applies only to carcinomas and melanomas and does not apply to lymphomas or sarcomas.

Carcinomas of the Oropharynx and Hypopharynx
- Squamous cell carcinoma
  - Human papillomavirus (HPV)-mediated (positive) squamous cell carcinoma (oropharynx only)\# 
  - HPV-unrelated (negative) squamous cell carcinoma (oropharynx and hypopharynx)\# 

Variants of Squamous Cell Carcinoma
- Keratinizing
- Nonkeratinizing
- Acantholytic squamous cell carcinoma
- Adenosquamous carcinoma
- Basaloid squamous cell carcinoma
- Papillary squamous cell carcinoma
- Spindle cell squamous cell carcinoma
- Verrucous squamous cell carcinoma
- Lymphoepithelial carcinoma

# Modification based on separation of HPV-mediated (positive) and HPV-unrelated (negative) oropharyngeal squamous cell carcinoma in the AJCC 8th edition and WHO 4th edition.

Carcinomas of the Nasopharynx
- Keratinizing squamous cell carcinoma
- Nonkeratinizing squamous cell carcinoma
- Basaloid squamous cell carcinoma
Adenocarcinomas Non-Salivary Gland Type
Nasopharyngeal papillary adenocarcinoma, low-grade

Carcinomas of the Minor Salivary Glands
The histologic classification recommended is a modification of the WHO classification of salivary gland tumors. Additional entities are covered in the major salivary gland protocol.

- Mucoepidermoid carcinoma
- Adenoid cystic carcinoma
- Acinic cell carcinoma
- Polymorphous adenocarcinoma
- (Mammary analogue) secretory carcinoma
- Salivary duct carcinoma
- Carcinoma ex pleomorphic adenoma
- Epithelial-myoepithelial carcinoma
- (Hyalinizing) clear cell carcinoma
- Adenocarcinoma, not otherwise specified
- Basal cell adenocarcinoma
- Carcinosarcoma
- Intraductal carcinoma
- Lymphoepithelial carcinoma
- Myoepithelial carcinoma
- Oncocytic carcinoma

Neuroendocrine Carcinoma
- Small cell neuroendocrine carcinoma, HPV negative
- Small cell neuroendocrine carcinoma, HPV positive
- Large cell neuroendocrine carcinoma, HPV negative
- Large cell neuroendocrine carcinoma, HPV positive

Mucosal Melanoma

C. Histologic Grade
For histologic types of carcinomas that are amenable to grading, 3 histologic grades are suggested, as shown below. For conventional squamous cell carcinoma, histologic grading as a whole does not perform well as a prognosticator. Nonetheless, it should be recorded when applicable, as it is a basic tumor characteristic. Specifically, it is only applicable for HPV-unrelated/negative oropharyngeal carcinomas and hypopharyngeal carcinomas. HPV-mediated/positive squamous cell carcinoma is not graded, and nasopharyngeal carcinoma is typed as above but does not otherwise require grading. Selecting either the most prevalent grade or the highest grade for this synoptic protocol is acceptable. Variants of squamous cell carcinoma (ie, verrucous, basaloid, etc) have an intrinsic biologic potential and currently do not appear to require grading.

- Grade 1 Well differentiated
- Grade 2 Moderately differentiated
- Grade 3 Poorly differentiated
- Grade X Cannot be assessed

The histologic (microscopic) grading of salivary gland carcinomas has been shown to be an independent predictor of behavior and plays a role in optimizing therapy. Further, there is often a positive correlation between histologic grade and clinical stage. However, most salivary gland carcinoma types have an intrinsic biologic behavior, and attempted application of a universal grading scheme is merely a crude surrogate. Thus, a generic grading scheme is no longer recommended for salivary gland carcinomas. Carcinoma types for which grading systems exist and are relevant are incorporated into histologic type. The 3 major categories that are amenable to grading include adenoid cystic carcinoma, mucoepidermoid carcinoma, and adenocarcinoma, not otherwise specified.
In some carcinomas, histologic grading may be based on growth pattern, such as in adenoid cystic carcinoma, for which a histologic high-grade variant has been recognized based on the percentage of solid growth. Those adenoid cystic carcinomas showing 30% or greater of solid growth pattern are considered to be histologically high-grade carcinomas. The histologic grading of mucoepidermoid carcinoma includes a combination of growth pattern characteristics (eg, cystic, solid, neurotropism) and cytomorphologic findings (eg, anaplasia, mitoses, necrosis). Adenocarcinomas, not otherwise specified, do not have a formalized grading scheme and are graded intuitively based on cytomorphologic features. Polymorphous adenocarcinomas are to be graded as per current WHO recommendations, though these are also graded intuitively as there are no listed criteria.

Carcinoma ex pleomorphic adenoma is subclassified by histologic type and or grade and extent of invasion, the latter including minimally invasive, widely invasive, and intracapsular (noninvasive) cancers. Previously the cut-off for minimal invasion was designated as 1.5 mm; however, more recent studies have shown a favorable prognosis even with cut-offs of 4 mm to 6 mm. Thus, there is no agreement on an optimal cut-off. However, from a practical standpoint, the terms intracapsular, and minimally invasive should only be applied to uninodular tumors (as opposed to carcinomas arising in multinodular recurrent pleomorphic adenomas) with a well-delineated interface for which the entire lesional border has been microscopically evaluated. Prognosis has been linked to degree of invasion with noninvasive and minimally invasive cancers apparently having a better prognosis than invasive cancers.

D. Surgical Margins
Historically, documentation of margin status for many oropharyngeal and hypopharyngeal tumors was not possible, and they were not oncologically resected but rather treated with chemotherapy and radiation. With the advent of transoral robotic and laser surgery, however, intact resections have become increasingly common. Limited evidence suggests that at the very minimum, a positive margin is represented by invasive carcinoma present at margin (microscopic cut-through of tumor). Akin to other sites, there is no standard definition of a “close” margin, and definitions have ranged from 2 mm to 5 mm. Despite the paucity of data, in keeping with other sites, the distance from the nearest margin should be recorded.

For hypopharyngeal and HPV-negative oropharyngeal tumors, in situ disease and high-grade dysplasia is plausible, and if present at a margin, the margin is considered positive in line with other sites. When such lesions are identified in pharyngeal sites, it usually occurs in association with an invasive carcinoma. In this setting, the same criteria detailed in the oral cavity and laryngeal protocols apply (see Protocol for the Examination of Specimens from Patients with Carcinomas of the Lip and Oral Cavity and Protocol for the Examination of Specimens from Patients with Carcinomas of the Larynx).

For HPV-positive oropharyngeal carcinoma, in situ disease for practical purposes nonexistent, likely given their derivation from the specialized "lymphoepithelium" of tonsillar crypt. Nasopharyngeal tumors are still generally not resected and margin status is usually not able to be documented.

E. Orientation of Specimen
Complex specimens should be examined and oriented with the assistance of the operating surgeon(s). Direct communication between the surgeon and pathologist is a critical component in specimen orientation and proper sectioning. Whenever possible, the tissue examination request form should include a drawing or photograph of the resected specimen showing the extent of the tumor and its relation to the anatomic structures of the region. The lines and extent of the resection can be depicted on preprinted adhesive labels and attached to the surgical pathology request forms.

F. Perineural Invasion
Traditionally, the presence of perineural invasion (neurotropism) is an important predictor of poor prognosis in head and neck cancer of virtually all sites. The presence of perineural invasion (neurotropism) in the primary cancer is associated with poor local disease control and regional control, as well as being associated with metastasis to regional lymph nodes. Further, perineural invasion is associated with decrease in disease-specific survival and overall survival. There is conflicting data relative to an association between the presence of perineural invasion and the development of distant metastasis, with some studies showing an increased
association with distant metastasis, while other studies showing no correlation with distant metastasis.\textsuperscript{25} The relationship between perineural invasion and prognosis is independent of nerve diameter.\textsuperscript{26} Additionally, emerging evidence suggests that extratumoral perineural invasion may be more prognostically relevant.\textsuperscript{27} Although perineural invasion of small unnamed nerves may not produce clinical symptoms, the reporting of perineural invasion includes nerves of all sizes including small peripheral nerves (ie, less than 1 mm in diameter). Aside from the impact on prognosis, the presence of perineural invasion also guides therapy. Concurrent adjuvant chemoradiation therapy has been shown to improve outcomes in patients with perineural invasion (as well as in patients with extranodal extension and bone invasion).\textsuperscript{28,29} While oropharyngeal, hypopharyngeal, and nasopharyngeal site specific data are limited, given the significance relative to prognosis and treatment for head and neck cancers in general, perineural invasion is a required data element in the reporting at these sites as well.

\section*{G. Lymph Nodes}

\subsection*{Measurement of Tumor Metastasis}

The cross-sectional diameter of the largest lymph node metastasis (not the lymph node itself) is measured in the gross specimen at the time of macroscopic examination or, if necessary, on the histologic slide at the time of microscopic examination.\textsuperscript{28,29}

\subsection*{Special Procedures for Lymph Nodes}

The risk of regional (cervical neck) nodal spread from cancers of the pharynx is high. The majority of metastatic carcinomas to the cervical lymph nodes take origin from a head and neck primary carcinoma. The most common histologic type of carcinoma to metastasize to cervical neck lymph nodes is squamous cell carcinoma. Cervical nodal metastases may occur in the setting of an unknown primary carcinoma referred to as metastatic cervical carcinoma with an unknown primary (CUP).

As per AJCC 8\textsuperscript{th} edition guidelines,\textsuperscript{30} 3 separate approaches are employed to stage patients who present with an occult primary tumor. The primary T category is described as T0 and the N category is designated according to the respective anatomic site based on Epstein-Barr virus (EBV) and HPV status:

1. Patients with EBV-related cervical adenopathy are staged according to N staging in nasopharynx.
2. Patients with HPV-mediated (positive) cervical adenopathy are staged according to N staging in HPV-mediated/ p16 positive oropharyngeal cancer.
3. All other patients with EBV-unrelated and HPV-unrelated cervical adenopathy are staged according to the generic N stage category used for the other head and neck sites, and for unknown primary.

This takes into account the site-specific differences in prognostic impact for metastatic nodal disease. Both HPV- and EBV-driven nodal metastases are typically nonkeratinizing, with the former often being cystic. When encountering this morphology, HPV and EBV testing as suggested in the CAP Head and Neck Biomarker template is critical.

Aside from these, no additional special techniques are required other than routine histology for the assessment of nodal metastases. Immunohistochemistry and polymerase chain reaction (PCR) to detect isolated tumor cells are considered investigational techniques at this time.

\subsection*{Regional Lymph Nodes (pN0): Isolated Tumor Cells}

Isolated tumor cells (ITCs) are single cells or small clusters of cells not more than 0.2 mm in greatest dimension. While the generic recommendation is that for lymph nodes with ITCs found by either histologic examination, immunohistochemistry, or nonmorphologic techniques (eg, flow cytometry, DNA analysis, PCR amplification of a specific tumor marker), they should be classified as N0 or M0, respectively.\textsuperscript{31,32} Evidence for the validity of this practice in head and neck squamous cell carcinoma and other histologic subtypes is lacking. In fact, rare studies relevant to head and neck sites indicate that isolated tumor cells may actually be a poor prognosticator in terms of local control.\textsuperscript{33}
Lymph Node Number
For assessment of pN, a selective neck dissection will ordinarily include 10 or more lymph nodes, and a comprehensive neck dissection (radical or modified radical neck dissection) will ordinarily include 15 or more lymph nodes. Examination of fewer tumor-free nodes still mandates a pN0 designation.

Classification of Neck Dissection
1. Radical neck dissection
2. Modified radical neck dissection, internal jugular vein and/or sternocleidomastoid muscle spared
3. Selective neck dissection (SND), as specified by the surgeon (Figure 3), defined by dissection of less than the 5 traditional levels of a radical and modified radical neck dissection. The following dissections are now under this category34-36:
   a. Supraomohyoid neck dissection
   b. Posterolateral neck dissection
   c. Lateral neck dissection
   d. Central compartment neck dissection
4. Superselective neck dissection (SSND), a relatively new term defined by dissection of the fibrofatty elements of 2 or less levels.37
5. Extended radical neck dissection, as specified by the surgeon

For purposes of pathologic evaluation, lymph nodes are organized by levels as shown in Figure 4.

Figure 4. The six sublevels of the neck for describing the location of lymph nodes within levels I, II, and V. Level IA, submental group; level IB, submandibular group; level IIA, upper jugular nodes along the carotid sheath, including the subdigastric group; level IIB, upper jugular nodes in the submuscular recess; level VA, spinal accessory nodes; and level VB, the supraclavicular and transverse cervical nodes. From Flint PW et al, eds. Cummings Otolaryngology: Head and Neck Surgery. 5th ed. Philadelphia, PA; Saunders: 2010. Reproduced with permission © Elsevier.

In order for pathologists to properly identify these nodes, they must be familiar with the terminology of the regional lymph node groups and with the relationships of those groups to the regional anatomy. Which lymph node groups surgeons submit for histopathologic evaluation depends on the type of neck dissection they perform. Therefore, surgeons must supply information on the types of neck dissections that they perform and on the details of the local anatomy in the specimens they submit for examination or, in other manners, orient those specimens for pathologists.

If it is not possible to assess the levels of lymph nodes (for instance, when the anatomic landmarks in the excised specimens are not specified), then the lymph node levels may be estimated as follows: level II, upper third of
internal jugular (IJ) vein or neck specimen; level III, middle third of IJ vein or neck specimen; level IV, lower third of IJ vein or neck specimen, all anterior to the sternocleidomastoid muscle.

**Level I. Submental Group (Sublevel IA)**
Lymph nodes within the triangular boundary of the anterior belly of the digastric muscles and the hyoid bone.

**Level I. Submandibular Group (Sublevel IB)**
Lymph nodes within the boundaries of the anterior and posterior bellies of the digastric muscle and the body of the mandible. The submandibular gland is included in the specimen when the lymph nodes within this triangle are removed.

**Level II. Upper Jugular Group (Sublevels IIA and IIB)**
Lymph nodes located around the upper third of the internal jugular vein and adjacent spinal accessory nerve extending from the level of the carotid bifurcation (surgical landmark) or hyoid bone (clinical landmark) to the skull base. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

**Level III. Middle Jugular Group**
Lymph nodes located around the middle third of the internal jugular vein extending from the carotid bifurcation superiorly to the omohyoid muscle (surgical landmark), or cricothyroid notch (clinical landmark) inferiorly. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

**Level IV. Lower Jugular Group**
Lymph nodes located around the lower third of the internal jugular vein extending from the omohyoid muscle superiorly to the clavicle inferiorly. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

**Level V. Posterior Triangle Group (Sublevels VA and VB)**
This group comprises predominantly the lymph nodes located along the lower half of the spinal accessory nerve and the transverse cervical artery. The supraclavicular nodes are also included in this group. The posterior boundary of the posterior triangle is the anterior border of the trapezius muscle, the anterior boundary of the posterior triangle is the posterior border of the sternocleidomastoid muscle, and the inferior boundary of the posterior triangle is the clavicle.

**Level VI. Anterior (Central) Compartment**
Lymph nodes in this compartment include the pre- and paratracheal nodes, precricoid (Delphian) node, and the perithyroidal nodes, including the lymph nodes along the recurrent laryngeal nerve. The superior boundary is the hyoid bone, the inferior boundary is the suprasternal notch, the lateral boundaries are the common carotid arteries, and the posterior boundary by the prevertebral fascia.

**Level VII. Superior Mediastinal Lymph Nodes**
Metastases at level VII are considered regional lymph node metastases; all other mediastinal lymph node metastases are considered distant metastases.

Lymph node groups removed from areas not included in the above levels, eg, scalene, suboccipital, and retropharyngeal, should be identified and reported from all levels separately. When staging lymph node involvement by metastases from nasopharyngeal carcinoma, the supraclavicular fossa refers to a triangular region, the base of which is the superior margin of the clavicle between its sternal and lateral ends, and the apex of which is the point where the neck meets the shoulder. This includes caudal portions of Levels IV and V (see above). All cancers metastatic to the posterior nodes in the supraclavicular fossa are designated as N3b. Midline nodes are considered ipsilateral nodes.
**Extranodal Extension**

The status of cervical lymph nodes is the single most important prognostic factor in aerodigestive cancer. All macroscopically negative or equivocal lymph nodes should be submitted in toto. Grossly positive nodes may be partially submitted for microscopic documentation of metastasis. For HPV-unrelated/p16-negative oropharyngeal cancers and hypopharyngeal cancers, reporting of lymph nodes containing metastasis should include whether there is presence or absence of extranodal extension (ENE).\(^{38}\) which is now part of N staging for these tumor types. This finding consists of extension of metastatic tumor, present within the confines of the lymph node, through the lymph node capsule into the surrounding connective tissue, with or without associated stromal reaction. A distance of extension from the native lymph node capsule is now suggested (but not yet required) with the proposed stratification of ENE into ENE\(_{ma}\) (>2 mm) and ENE\(_{mi}\) (≤2 mm).\(^{39-42}\) However, pitfalls in the measurement (ie, in larger, matted lymph nodes, in nodes post fine-needle aspiration, and in nodes with near total replacement of lymph node architecture) and the disposition of soft tissue deposits is still not resolved. In general, absence of ENE in a large (>3 cm) lymph node, especially with traversing fibrous bands, should be viewed with skepticism. Soft tissue deposits for lymph node metastases based on limited studies appear to be the equivalent of a positive lymph node with ENE and should be recorded as such.\(^{43}\)

However, ENE does not appear to be as prognostically relevant for HPV-mediated/p16-positive and nasopharyngeal cancers. While it may be recorded, it is not required under AJCC guidelines.\(^{3,4}\)

**H. TNM and Stage Groupings**

The protocol recommends the TNM staging system of the American Joint Committee on Cancer and the International Union Against Cancer for the oropharynx, nasopharynx, and hypopharynx.\(^2-4\) AJCC 8\(^{th}\) edition staging has introduced several changes. Notably HPV-mediated (p16-positive) squamous cell carcinomas of the oropharynx have their own staging system, with respect to both T and N stage. ENE is not relevant to this category and is not incorporated into the N stage. However, ENE is still required for N staging of HPV-unrelated (p16-negative) squamous cell carcinoma and hypopharyngeal carcinomas. For nasopharyngeal carcinomas, T stage has been revised. The extent of structural involvement for T2 and T4 in particular have been redefined. T2 denotes tumors with extension to parapharyngeal space and/or adjacent soft tissue involvement (medial pterygoid, lateral pterygoid, prevertebral muscles). T4 indicates tumor with intracranial extension, involvement of cranial nerves, hypopharynx, orbit, parotid gland, and/or extensive soft tissue infiltration beyond the lateral surface of the lateral pterygoid muscle. Additionally, N stage for nasopharyngeal squamous cell carcinoma has been simplified, removing N3a and N3b substratification. The anatomic border for defining N3 has been revised from supravacular fossa (Level VB) to caudal border of the cricoid cartilage (Level IV, and VB). T and N anatomic definitions are summarized in Figure 3.
Figure 3. Differences in defining criteria between the 7th edition and the 8th edition for staging of NPC: (A) changing the extent of soft tissue involvement as T2 and T4 criteria. Abbreviations: CS = carotid space, LP = lateral pterygoid muscle, M = masseter muscle, MP = medial pterygoid muscle, PG = parotid gland, PPS = parapharyngeal space, PV = prevertebral muscle, T = temporalis muscle; (B) replacing supraclavicular fossa (blue) by lower neck, ie, below caudal border of cricoid cartilage (red) as N3 criteria. From AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017. © American Joint Committee on Cancer. Reproduced with permission.

The 8th edition of the AJCC staging of head and neck cancers includes mucosal melanomas; this does not show significant changes from the 7th edition. Approximately two-thirds of mucosal melanomas arise in the sinonasal tract, one-quarter are found in the oral cavity, and the remainder occur only sporadically in other mucosal sites of the head and neck. Even small cancers behave aggressively with high rates of recurrence and death. To reflect this aggressive behavior, primary cancers limited to the mucosa are considered T3 lesions. Advanced mucosal melanomas are classified as T4a and T4b. The anatomic extent criteria to define moderately advanced (T4a) and very advanced (T4b) disease are given below. The AJCC staging for mucosal melanomas does not provide for the histologic definition of a T3 lesion; as the majority of mucosal melanomas are invasive at presentation, mucosal-based melanomas (T3 lesions) include those lesions that involve either the epithelium and/or lamina propria of the involved site. Rare examples of in situ mucosal melanomas occur, but in situ mucosal melanomas are excluded from staging, as they are extremely rare.

Carcinomas of minor salivary glands of the upper aerodigestive tract site, including the oral cavity, are staged according to schemes corresponding to the anatomic site of occurrence. There is no currently accepted staging for central (primary intraosseous) salivary gland tumors.

By AJCC/UICC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on clinical stage information supplemented/modified by operative findings and gross and microscopic evaluation of the resected specimens. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically unfeasible) and if the
highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

**Stage Groupings – For All Carcinomas**

**HPV-Mediated (positive) Oropharynx**

<table>
<thead>
<tr>
<th>Stage</th>
<th>T0, T1, T2</th>
<th>N0, N1</th>
<th>M0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td>T0, T1, T2</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td>Stage II</td>
<td>T3 or T4</td>
<td>N0, N1</td>
<td>M0</td>
</tr>
<tr>
<td>Stage III</td>
<td>T3 or T4</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IV</td>
<td>Any T</td>
<td>Any N</td>
<td>M0</td>
</tr>
</tbody>
</table>

**HPV-Unrelated (Negative) Oropharynx and Hypopharynx**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Tis</th>
<th>N0</th>
<th>M0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage II</td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage III</td>
<td>T1, T2</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IV</td>
<td>T3</td>
<td>N0, N1</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVA</td>
<td>T1, T2, T3</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVB</td>
<td>Any T</td>
<td>N3</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVC</td>
<td>Any T</td>
<td>Any N</td>
<td>M0</td>
</tr>
</tbody>
</table>

**Nasopharynx**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Tis</th>
<th>N0</th>
<th>M0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage II</td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage III</td>
<td>T0, T1, T2</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IV</td>
<td>T0, T1, T2</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVA</td>
<td>Any T</td>
<td>N3</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVB</td>
<td>Any T</td>
<td>Any N</td>
<td>M0</td>
</tr>
</tbody>
</table>

**Stage Groupings – For Mucosal Melanoma**

<table>
<thead>
<tr>
<th>Stage</th>
<th>T3</th>
<th>N0</th>
<th>M0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage IVA</td>
<td>T4a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVB</td>
<td>T4b</td>
<td>Any N</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVC</td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
</tr>
</tbody>
</table>

**TNM Descriptors**

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y” and “r” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The "m" suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The "y" prefix indicates those cases in which classification is performed during or following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (ie, before initiation of neoadjuvant therapy).
The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.

Additional Descriptors

Residual Tumor (R)
Tumor remaining in a patient after therapy with curative intent (e.g., surgical resection for cure) is categorized by a system known as R classification, shown below.

RX  Presence of residual tumor cannot be assessed
R0  No residual tumor
R1  Microscopic residual tumor
R2  Macroscopic residual tumor

For the surgeon, the R classification may be useful to indicate the known or assumed status of the completeness of a surgical excision. For the pathologist, the R classification is relevant to the status of the margins of a surgical resection specimen. That is, tumor involving the resection margin on pathologic examination may be assumed to correspond to residual tumor in the patient and may be classified as macroscopic or microscopic according to the findings at the specimen margin(s).

I. Dysplasia of the Upper Aerodigestive Tract (UADT)
The concept of epithelial precursor lesions, including dysplasia and carcinoma in situ of the oropharyngeal (base of tongue and tonsils) and nasopharyngeal mucosa, are not well defined. In biopsies of nasopharyngeal carcinoma, only a minority of cases (less than 10%) will have an in situ component. Further, carcinoma in situ of the oropharynx and nasopharynx as confirmed by biopsy to rule out an invasive carcinoma component is very rare. Histologically, carcinoma in situ of the oropharynx and nasopharynx may be confined to the surface or crypt epithelium without invasive carcinoma and, when present, are most often of the nonkeratinizing type. Hypopharyngeal precursor lesions are rarely identified as hypopharyngeal cancers by virtue of their anatomic site and often remain clinically quiescent commonly presenting as invasive carcinomas.

References


